These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 14965491)

  • 41. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists.
    Huxtable LM; Tafreshi MJ; Rakkar AN
    Am J Cardiol; 2006 Feb; 97(3):426-9. PubMed ID: 16442410
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
    Day JR; Malik IS; Weerasinghe A; Poullis M; Nadra I; Haskard DO; Taylor KM; Landis RC
    Heart; 2004 Jul; 90(7):794-9. PubMed ID: 15201252
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty.
    Mazurov AV; Pevzner DV; Antonova OA; Byzova TV; Khaspekova SG; Semenov AV; Vlasik TN; Samko AN; Staroverov II; Ruda MY
    Platelets; 2002 Dec; 13(8):465-77. PubMed ID: 12487780
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
    Keating FK; Whitaker DA; Sobel BE; Schneider DJ
    Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vanishing platelets: rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction.
    Rahman N; Jafary FH
    Tex Heart Inst J; 2010; 37(1):109-12. PubMed ID: 20200641
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Inhibitors of GPIIb/IIIa platelet receptors].
    Chanu B
    Arch Mal Coeur Vaiss; 1999 Jul; 92(7):893-902. PubMed ID: 10443310
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety evaluation of tirofiban.
    Valgimigli M; Tebaldi M
    Expert Opin Drug Saf; 2010 Sep; 9(5):801-19. PubMed ID: 20670206
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events.
    Dunkley S; Evans S; Gaudry L; Jepson N
    Platelets; 2005 Dec; 16(8):462-8. PubMed ID: 16287613
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
    Wang X; Dorsam RT; Lauver A; Wang H; Barbera FA; Gibbs S; Varon D; Savion N; Friedman SM; Feuerstein GZ
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1114-20. PubMed ID: 12438534
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.
    Schwarz M; Meade G; Stoll P; Ylanne J; Bassler N; Chen YC; Hagemeyer CE; Ahrens I; Moran N; Kenny D; Fitzgerald D; Bode C; Peter K
    Circ Res; 2006 Jul; 99(1):25-33. PubMed ID: 16778135
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Platelet glycoprotein IIb/IIIa inhibition and its clinical use.
    Huang F; Hong E
    Curr Med Chem Cardiovasc Hematol Agents; 2004 Jul; 2(3):187-96. PubMed ID: 15320785
    [TBL] [Abstract][Full Text] [Related]  

  • 54. AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists.
    Hantgan RR; Stahle MC; Connor JH; Connor RF; Mousa SA
    J Thromb Haemost; 2007 Mar; 5(3):542-50. PubMed ID: 17166246
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition.
    Li YF; Spencer FA; Becker RC
    Am Heart J; 2002 Apr; 143(4):725-32. PubMed ID: 11923812
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions.
    Goto S; Tamura N; Ishida H
    J Am Coll Cardiol; 2004 Jul; 44(2):316-23. PubMed ID: 15261925
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of glycoprotein IIb/IIIa inhibition in the management of acute coronary syndromes.
    Koller CF
    Heart Lung; 2001; 30(5):321-9; quiz 330-1. PubMed ID: 11604974
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro.
    Hamilton SF; Miller MW; Thompson CA; Dale GL
    J Lab Clin Med; 2004 May; 143(5):320-6. PubMed ID: 15122176
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Successful use of eptifibatide as an adjunct to coronary stenting in a patient with abciximab-associated acute profound thrombocytopenia.
    Rao J; Mascarenhas DA
    J Invasive Cardiol; 2001 Jun; 13(6):471-3. PubMed ID: 11385174
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Profound thrombocytopenia associated with tirofiban: case report and review of literature.
    Patel S; Patel M; Din I; Reddy CV; Kassotis J
    Angiology; 2005; 56(3):351-5. PubMed ID: 15889207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.